BridgeBio Pharma (Nasdaq: BBIO) announced positive Phase 2 proof-of-concept results for encaleret in treating post-surgical hypoparathyroidism. The study showed that 80% of participants achieved normal blood and urine calcium levels within 5 days of treatment, compared to 0% on conventional therapy.
The oral therapy demonstrated PTH-independent normalization of calcium levels, with nine participants showing rapid and sustained reduction in fractional excretion of calcium. The drug was well-tolerated with no serious adverse events reported. Based on these promising results, BridgeBio plans to initiate a registrational clinical study in 2026.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.